RxDoctor Payments Data

Nicole Pierre-Noel

Family · New York, NYNPI 1609186113

Payments from drug & device makers

$3,039in general payments, 2019–2025

Across 30 payments — averaging $101.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$251
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$249
  • Sage Therapeutics, LLC$245
  • Biogen$193
  • Biomerieux Inc$142
  • Novartis$140
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$3,039100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,039 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$87,016
JanuviaSitagliptin Phosphate83$83,851
TrulicityDulaglutide35$46,758
EliquisApixaban34$44,075
FarxigaDapagliflozin Propanediol11$9,191
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$4,006
Nateglinide57$3,755
Atorvastatin Calcium316$3,722
Tresiba Flextouch U-200Insulin Degludec18$3,438
Losartan Potassium216$2,219
Amlodipine Besylate295$1,688
Levothyroxine Sodium80$1,583
Metoprolol Succinate108$1,566
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,300
Albuterol Sulfate HfaAlbuterol Sulfate35$1,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$121$87,01687 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →